4-甲氧基-N,N-二甲基-2-嘧啶胺 | 1197-11-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 4-甲氧基-N,N-二甲基-2-嘧啶胺
• 英文名称: 2-Dimethylamino-4-methoxy-pyrimidin
• 英文别名: 4-methoxy-N,N-dimethylpyrimidin-2-amine
• CAS: 1197-11-1
• 化学式: C₇H₁₁N₃O
• mdl: MFCD09802141
• 分子量: 153.184
• InChiKey: FKMDHVOHDANIDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

文献信息

• [EN] NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE HYDROXY-6-HÉTÉROARYLPHÉNANTHRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PDE4
  申请人：ALTANA PHARMA AG

  公开号：WO2005085225A1

  公开（公告）日：2005-09-15

  Compounds of formula (I), in which R1 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy, R2 is hydroxyl, 1-4C-alkoxy, 3-7C-cycloalkoxy, 3-7C-cycloalkylmethoxy, 2,2-difluoroethoxy, or completely or predominantly fluorine-substituted 1-4C-alkoxy, or in which R1 and R2 together are a 1-2C-alkylenedioxy group, R3 is hydrogen or 1-4C-alkyl, R31 is hydrogen or 1-4C-alkyl, either, in a first embodiment (embodiment a) according to the present invention, R4 is -O-R41, in which R41 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, hydroxy-2-4C-alkyl, 1-7C-alkylcarbonyl, or completely or predominantly fluorine-substituted 1-4C-alkyl, and R5 is hydrogen or 1-4C-alkyl, or, in a second embodiment (embodiment b) according to the present invention, R4 is hydrogen or 1-4C-alkyl, and R5 is -O-R51, in which R51 is hydrogen, 1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, hydroxy-2-4C-alkyl, 1-7C-alkylcarbonyl, or completely or predominantly fluorine-substituted 1-4C-alkyl, Har is optionally substituted by R6 and/or R7 and/or R8, and is a 5- to 10-membered monocylic or fused bicyclic unsaturated or partially saturated heteroaryl radical comprising 1 to 4 heteroatoms selected independently from the group consisting of oxygen, nitrogen and sulfur, are novel effective PDE4 inhibitors.

  公式（I）中的化合物，其中R1是羟基，1-4C-烷氧基，3-7C-环氧基，3-7C-环烷基甲氧基，2,2-二氟乙氧基，或完全或主要氟代的1-4C-烷氧基，R2是羟基，1-4C-烷氧基，3-7C-环氧基，3-7C-环烷基甲氧基，2,2-二氟乙氧基，或完全或主要氟代的1-4C-烷氧基，或者R1和R2一起是1-2C-烷二氧基基团，R3是氢或1-4C-烷基，R31是氢或1-4C-烷基，在本发明的第一实施例（实施例a）中，R4是-O-R41，其中R41是氢，1-4C-烷基，1-4C-烷氧基-1-4C-烷基，羟基-2-4C-烷基，1-7C-烷基羰基，或完全或主要氟代的1-4C-烷基，而R5是氢或1-4C-烷基，或者在本发明的第二实施例（实施例b）中，R4是氢或1-4C-烷基，而R5是-O-R51，其中R51是氢，1-4C-烷基，1-4C-烷氧基-1-4C-烷基，羟基-2-4C-烷基，1-7C-烷基羰基，或完全或主要氟代的1-4C-烷基，Har可选地由R6和/或R7和/或R8取代，并且是包含1至4个异原子（独立选择自氧、氮和硫组成的）的5-到10-成员单环或融合的双环不饱和或部分饱和杂环基团，是新颖的有效PDE4抑制剂。
• Glycine Derivative and Use Thereof
  申请人：Hirano Noriyuki

  公开号：US20080085910A1

  公开（公告）日：2008-04-10

  A glycine derivative which is, e.g., the following compound (Chemical formula (1)). It is highly effective in the treatment and prevention of inflammatory bowel diseases. Compared to conventional compounds, the compound is excellent in absorbability in oral administration and in vivo stability. The compound can be orally administered and can retain an excellent therapeutic or preventive effect over a longer period.

  一种甘氨酸衍生物，例如以下化合物（化学式（1））。它在治疗和预防炎症性肠病方面非常有效。与传统化合物相比，该化合物在口服吸收和体内稳定性方面表现出色。该化合物可以口服给药，并能在较长时间内保持出色的治疗或预防效果。
• THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA
  申请人：Kaino Mie

  公开号：US20090253724A1

  公开（公告）日：2009-10-08

  A therapeutic or prophylactic agent for leukemia is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for leukemia according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits prominent therapeutic or prophylactic effects.

  本发明揭示了一种治疗或预防白血病的药剂。该治疗或预防药剂包含一种具有特定结构的甘氨酸衍生物或其药学上可接受的盐作为有效成分，例如下述化合物[(E)-2-(2,6-二氯苯甲酰胺基)-5-[4-(异丙基嘧啶-2-基)苯基]戊-4-烯酸]。本发明的白血病治疗或预防药剂在口服时表现出优异的吸收性和体内稳定性，并展现出显著的治疗或预防效果。
• THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS
  申请人：Toray Industries, Inc.

  公开号：EP2042171B1

  公开（公告）日：2011-05-11
• THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS
  申请人：Toray Industries, Inc.

  公开号：EP2039687B1

  公开（公告）日：2012-05-02